GoAI
Get started
Shanghai HeartCare Medical Technology Corporation Limited logo

Shanghai HeartCare Medical Technology Corporation Limited

6609.HK

HKSEHealthcareMedical - Devices

Open in GoAI

Latest quote

HK$49.58

−HK$0.34 · -0.68%

Aug 24, 3:55 PM HKT

6609.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Shanghai HeartCare Medical Technology Corporation Limited is a global enterprise specializing in the research, development, manufacturing, and commercialization of neuro-interventional medical devices. Its extensive product range encompasses devices for ischemic stroke thrombectomy, intracranial stenosis intervention, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access. These medical technologies are utilized for both the prevention and treatment of ischemic stroke, including acute ischemic events and intracranial narrowing, as well as for addressing hemorrhagic stroke. Established in 2016 and previously operating as Shanghai Care Medical Technology Corporation Limited, the company maintains its headquarters in Shanghai, People's Republic of China.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
CN
CEO
Guohui Wang
Listed since
Aug 20, 2021
Employees
368

Market position

Volume
5.85K
0.11× average
Average volume
51.66K
Average daily volume
Market cap
1.87B HKD
Beta
0.63
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.28B CNY
P/E (TTM)
19.35×
P/B (TTM)
1.42×
P/S (TTM)
3.94×
EV / EBITDA
19.87×
Earnings yield
4.56%
Free cash flow yield
7.66%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
66.66%
Operating margin
10.85%
Net margin
20.41%
Return on equity
7.36%
Return on assets
6.45%
Return on invested capital
3.54%

Financial health

Debt / equity
0.04×
Current ratio
11.49×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends96%-17%-131%-244%Gross margin, FY2021: 61.00%Gross margin, FY2022: 67.93%Gross margin, FY2023: 65.33%Gross margin, FY2024: 65.39%Gross margin, FY2025: 66.66%Operating margin, FY2021: -173.57%Operating margin, FY2022: -108.49%Operating margin, FY2023: -54.20%Operating margin, FY2024: -2.24%Operating margin, FY2025: 10.85%Net margin, FY2021: -215.59%Net margin, FY2022: -109.48%Net margin, FY2023: -40.46%Net margin, FY2024: -4.90%Net margin, FY2025: 20.41%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 61.00%. Gross margin FY2022 67.93%. Gross margin FY2023 65.33%. Gross margin FY2024 65.39%. Gross margin FY2025 66.66%. Operating margin FY2021 -173.57%. Operating margin FY2022 -108.49%. Operating margin FY2023 -54.20%. Operating margin FY2024 -2.24%. Operating margin FY2025 10.85%. Net margin FY2021 -215.59%. Net margin FY2022 -109.48%. Net margin FY2023 -40.46%. Net margin FY2024 -4.90%. Net margin FY2025 20.41%.

Income trends

Revenue

408.29M CNY+46.92%

Operating income

44.29M CNY+50.52M CNY

Net income

83.34M CNY+96.96M CNY
Income trends across reported periods469.15M CNY225.69M CNY−17.78M CNY−261.25M CNYRevenue, FY2021: 90.09M CNYRevenue, FY2022: 183.03M CNYRevenue, FY2023: 232.34M CNYRevenue, FY2024: 277.9M CNYRevenue, FY2025: 408.29M CNYOperating income, FY2021: −156.37M CNYOperating income, FY2022: −198.57M CNYOperating income, FY2023: −125.92M CNYOperating income, FY2024: −6.24M CNYOperating income, FY2025: 44.29M CNYNet income, FY2021: −194.23M CNYNet income, FY2022: −200.38M CNYNet income, FY2023: −94.01M CNYNet income, FY2024: −13.62M CNYNet income, FY2025: 83.34M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 90.09M CNY. Revenue FY2022 183.03M CNY. Revenue FY2023 232.34M CNY. Revenue FY2024 277.9M CNY. Revenue FY2025 408.29M CNY. Operating income FY2021 −156.37M CNY. Operating income FY2022 −198.57M CNY. Operating income FY2023 −125.92M CNY. Operating income FY2024 −6.24M CNY. Operating income FY2025 44.29M CNY. Net income FY2021 −194.23M CNY. Net income FY2022 −200.38M CNY. Net income FY2023 −94.01M CNY. Net income FY2024 −13.62M CNY. Net income FY2025 83.34M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue408.29M CNY277.9M CNY232.34M CNY183.03M CNY90.09M CNY
Cost of goods sold136.12M CNY96.18M CNY80.55M CNY58.7M CNY35.14M CNY
Gross profit272.17M CNY181.72M CNY151.79M CNY124.33M CNY54.95M CNY
Research and development40.76M CNY58.94M CNY123.83M CNY153.69M CNY76.31M CNY
Selling, general, and administrative187.12M CNY137.81M CNY153.88M CNY167.99M CNY167.02M CNY
Operating expenses227.88M CNY187.95M CNY277.71M CNY309.81M CNY211.32M CNY
Interest income6.24M CNY8.77M CNY11.2M CNY15.14M CNY5.5M CNY
Interest expense2.06M CNY1.75M CNY2.16M CNY2.15M CNY2.36M CNY
Depreciation and amortization20.16M CNY32.11M CNY32.26M CNY31.79M CNY12.2M CNY
Operating income44.29M CNY−6.24M CNY−125.92M CNY−198.57M CNY−156.37M CNY
Net income83.34M CNY−13.62M CNY−94.01M CNY−200.38M CNY−194.23M CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
57%
4 beats, 2 misses, 1 met estimate
Average EPS surprise
+32.79%
7 comparable reports
Latest EPS result
0.48
Estimate 1.64 · Miss by 70.83%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.930.53-0.88-2.28Q1 '24MetQ2 '24No estimateQ3 '24BeatQ3 '24BeatQ4 '24No estimateQ3 '25BeatQ1 '26MissQ3 '26Estimate
Q1 2024, reported Mar 28, 2024: actual -1.14, estimate -1.14, surprise 0.00%, Met estimate. Q2 2024, reported May 20, 2024: actual -0.073, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 30, 2024: actual -0.15, estimate -0.183, surprise +17.65%, Beat. Q3 2024, reported Sep 30, 2024: actual -0.125, estimate -0.234, surprise +46.80%, Beat. Q4 2024, reported Dec 31, 2024: actual -0.12, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 29, 2025: actual 1.45, estimate -1.34, surprise +208.46%, Beat. Q1 2026, reported Mar 26, 2026: actual 0.478, estimate 1.64, surprise -70.83%, Miss. Q3 2026, reported Aug 31, 2026: actual —, estimate -1.99, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates343.6M248.76M153.92M59.08MQ1 '24BeatQ2 '24No estimateQ3 '24MissQ3 '24MissQ4 '24No estimateQ3 '25BeatQ1 '26MissQ3 '26Estimate
Q1 2024, reported Mar 28, 2024: actual 135.05M HKD, estimate 132.67M HKD, surprise +1.80%, Beat. Q2 2024, reported May 20, 2024: actual 69.5M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 30, 2024: actual 138.05M HKD, estimate 156.12M HKD, surprise -11.57%, Miss. Q3 2024, reported Sep 30, 2024: actual 82.67M HKD, estimate 200.37M HKD, surprise -58.74%, Miss. Q4 2024, reported Dec 31, 2024: actual 79.47M HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 29, 2025: actual 203.29M HKD, estimate 193.84M HKD, surprise +4.88%, Beat. Q1 2026, reported Mar 26, 2026: actual 123.91M HKD, estimate 283.57M HKD, surprise -56.30%, Miss. Q3 2026, reported Aug 31, 2026: actual —, estimate 323.29M HKD, surprise —, Comparison unavailable.

6609.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 6609.HK

research.disclaimer